Aet­na is go­ing af­ter an­oth­er phar­ma­ceu­ti­cal com­pa­ny for al­leged price fix­ing. The health in­sur­ance provider ...

New an­ti-obe­si­ty drugs should meet a min­i­mum lev­el of weight loss to be con­sid­ered for ap­proval, the FDA said ...

Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...

This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...

Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area of focus for the drugmaker ...

Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...